Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Non-cash Items: 2022-2025

Historic Non-cash Items for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $4.8 million.

  • Mereo BioPharma Group's Non-cash Items fell 79.73% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 79.73%. This contributed to the annual value of $15.8 million for FY2024, which is 94.02% up from last year.
  • As of Q3 2025, Mereo BioPharma Group's Non-cash Items stood at $4.8 million, which was down 51.87% from $10.1 million recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Non-cash Items high stood at $23.9 million for Q3 2024, and its period low was $6,000 during Q4 2022.
  • Over the past 3 years, Mereo BioPharma Group's median Non-cash Items value was $12.9 million (recorded in 2024), while the average stood at $13.2 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Non-cash Items skyrocketed by 135,266.67% in 2023, and later crashed by 79.73% in 2025.
  • Mereo BioPharma Group's Non-cash Items (Quarterly) stood at $6,000 in 2022, then skyrocketed by 135,266.67% to $8.1 million in 2023, then soared by 94.02% to $15.8 million in 2024, then crashed by 79.73% to $4.8 million in 2025.
  • Its Non-cash Items stands at $4.8 million for Q3 2025, versus $10.1 million for Q2 2025 and $7.0 million for Q1 2025.